<table>
<thead>
<tr>
<th>CONTENTS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td><strong>Existing Grant Programmes:</strong></td>
<td></td>
</tr>
<tr>
<td>EFSD/Servier</td>
<td>6</td>
</tr>
<tr>
<td>European Research Programme on Vascular Complications of Type 2 Diabetes</td>
<td></td>
</tr>
<tr>
<td>EFSD/Lilly</td>
<td>7</td>
</tr>
<tr>
<td>European Diabetes Research Programme</td>
<td></td>
</tr>
<tr>
<td>EFSD/Novo Nordisk</td>
<td>8</td>
</tr>
<tr>
<td>Programme in Diabetes Research</td>
<td></td>
</tr>
<tr>
<td>EFSD/JDRF/Novo Nordisk</td>
<td>9</td>
</tr>
<tr>
<td>European Programme in Type 1 Diabetes Research</td>
<td></td>
</tr>
<tr>
<td>EFSD/LifeScan</td>
<td>11</td>
</tr>
<tr>
<td>European Studies on Glucose Monitoring</td>
<td></td>
</tr>
<tr>
<td>EFSD/MSD</td>
<td>12</td>
</tr>
<tr>
<td>Study Programme on Beta Cell Function &amp; Survival</td>
<td></td>
</tr>
<tr>
<td>EFSD/Pfizer</td>
<td>13</td>
</tr>
<tr>
<td>Resource Awards for Diabetes Research</td>
<td></td>
</tr>
<tr>
<td>EFSD/Medtronic</td>
<td>14</td>
</tr>
<tr>
<td>Clinical Research Grant on the Usefulness of CSII in Microalbuminuric Type 1 Diabetic Patients</td>
<td></td>
</tr>
<tr>
<td>EFSD/Amylin</td>
<td>15</td>
</tr>
<tr>
<td>Paul Langerhans Grant on the Integrated Physiology of the Entero-Insular Axis and the Brain in Metabolic Homeostasis</td>
<td></td>
</tr>
<tr>
<td>EFSD/sanofi-aventis</td>
<td>16</td>
</tr>
<tr>
<td>European Programme: The Endocannabinoid System from Bench to Bedside</td>
<td></td>
</tr>
<tr>
<td>European Programme for the Funding of Studies on the Management of Diabetes and Blood Glucose Abnormalities in Patients with Cardiovascular Disease</td>
<td></td>
</tr>
<tr>
<td>EFSD Grant Award</td>
<td>18</td>
</tr>
<tr>
<td>For Collaborative Diabetes Research between China and Europe supported by <strong>Bristol-Myers Squibb Company (BMS)</strong></td>
<td></td>
</tr>
</tbody>
</table>
## New/Renewed Grant Programmes for 2007:

**EFSD**
Clinical Research Grant in Type 2 Diabetes

**EFSD/Novartis**
European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction

**EFSD/AstraZeneca**
Young Investigator Awards

**EFSD/Novo Nordisk**
European Clinical Research Programme in Adolescents with Type 2 Diabetes

**EFSD/JDRF/Novo Nordisk**
European Programme in Type 1 Diabetes Research

*The above relates solely to programmes which have been officially agreed.*

## Existing Fellowships:

**EFSD/Eli Lilly Research Fellowships**

**EFSD/AstraZeneca Fellowships**
Islet Biology / Clinical Travel

**EFSD Travel Fellowships for Young Researchers from China**
supported by Bristol-Myers Squibb Company (BMS)

**EFSD/Albert Renold Fellowships**

---

**EFSD Review Committee Members**

**EFSD Executive Committee and Administration**
In 1999 the European Association for the Study of Diabetes (EASD) created its own Foundation - the European Foundation for the Study of Diabetes (EFSD) - in order to support more actively diabetes research in Europe and to serve even more effectively the goals of EASD, which are: to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge, and to facilitate its application.

EFSD is a non-profit foundation, which seeks to support the highest quality research in Europe to find a cure for all types of diabetes and associated complications and to prevent their onset. EFSD aims to co-operate with other government and non-government agencies in order to increase funding in European diabetes research as a means of achieving its goals. Through its various activities and programmes, the Foundation also strives to enhance awareness in Europe of the severity and magnitude of this devastating disease. It is the ambition of the Executive Committee to develop EFSD as the main European funding agency for diabetes research.

The Foundation is closely related to EASD; it is governed exclusively by the Executive Committee of EASD, which itself is under the close supervision of the EASD Council and General Assembly. The Foundation operates on a strictly non-profit basis under the control of the relevant authorities in Germany.

**Partnerships bring over Euro 37 Million to European diabetes research**

In order to foster diabetes research at the highest level in Europe, EFSD has entered into innovative partnerships with other foundations and with industry. Through such partnerships, to date EFSD has committed over **Euro 37 Million** to diabetes research in Europe.

Further information on EFSD Award Programmes is available on the web site of the Foundation: [www.EuropeanDiabetesFoundation.org](http://www.EuropeanDiabetesFoundation.org). An RFA (request for applications) for each programme is printed in *Diabetologia* (the official journal of EASD), and announced in the monthly e-mail sent to EASD members.

*All applications are subject to rigorous peer review by a fully independent panel of leading experts in the field, and awards are based on scientific merit. Applications from non-profit organisations are welcome from Europe or any associated country.*
GRANTS

AWARDED IN

2006
EFSD
and
Servier

European Research Programme on Vascular Complications of Type 2 Diabetes

Background

Servier is a research-based pharmaceutical company with an established reputation in diabetes research, therapeutics and education. Present in 135 countries worldwide, the company is proud to maintain a number of tight long-term collaborations with key diabetes organisations.

Plan

EFSD and Servier have established a European programme on vascular complications of type 2 diabetes to encourage quality new projects aimed at advancing current knowledge in this domain. Applications are particularly welcome for projects that aim to clarify the molecular mechanisms of vascular complications in type 2 diabetes. These grants are intended to stimulate and accelerate European research into the vascular complications of type 2 diabetes.

Funding Instruments

Initially, Euro 1.1 million was made available for the 3 year period 2002 - 2004. In 2004 the EFSD/Servier Programme was extended, with an additional Euro 1 million made available for the period 2005 - 2007.

Awards in 2006

Based on the recommendations of the Review Committee, the Programme Board made the following awards of up to Euro 100,000 each:

Zoltán Benyó: Ruprecht-Karls-University - Heidelberg, Germany
Rakesh Chibber: King's College - London, U.K.
Per-Anders Jansson: Göteborg University - Sweden
Åke Sjöholm: Karolinska Institute - Stockholm, Sweden
Vincenzo Trischitta: Mendel Institute - Rome, Italy
EFSD
and
Eli Lilly and Company

European Diabetes Research Programme

Background

Eli Lilly and Company is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Eli Lilly and Company is in Indianapolis, Indiana, USA.

Plan

The EFSD/Eli Lilly European Diabetes Research Programme is established within the frame of the Euro 2 million EFSD/Eli Lilly Fund. The goals of the Fund are: to promote increased European research in diabetes, support training and mobility programmes in diabetes research for young clinicians and scientists, and increase awareness of the burden of diabetes and its complications throughout Europe.

In 2005 the Fund committed a further Euro 1.8 million to European diabetes research for the 3 year period 2006-2008. This extends the original EFSD/Eli Lilly Fund with a new combined total of up to Euro 3.8 million.

Funding Instruments

The EFSD/Lilly Diabetes Research Programme made available a total of Euro 1 million for the three year period 2003 - 2005. In 2005 the Programme was extended, with an additional Euro 1.1 million made available for the period 2006 - 2008.

Awards in 2006

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 100,000:

Angelo Avogaro: University of Padova - Italy
Benoit Gauthier: University Medical Center - Geneva, Switzerland
Joanne Rasschaert: Brussels University – Belgium
Michele Solimena: Dresden University of Technology - Germany
Programme in Diabetes Research

Background

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 60 countries.

Plan

The EFSD/Novo Nordisk Programme in Diabetes Research will accept applications within any area of basic or clinical diabetes research. Those focusing on psycho-social aspects of diabetes management and on prevention will also be most welcome. All applications will be considered on an equal basis and judged on their intrinsic scientific merit.

Funding Instruments

Euro 2.1 million has been made available over 3 years for research in the framework of the Programme, which is carried out in Europe and its associated countries. Awards will be offered between 2004 and 2006 in the form of research grants of up to Euro 100,000 each.

Awards in 2006

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 100,000:

Sylvie Guerder: Toulouse Centre of Physiopathology - France
André Herchuelz: Brussels University - Belgium
Stephan Herzig: German Cancer Research Center - Heidelberg, Germany
Marta Hribal: Catanzaro Magna Graecia University - Italy
Pierre Maechler: Geneva University - Switzerland
Michael Roden: Hanusch Hospital - Vienna, Austria
Coen Stehouwer: Maastricht University - The Netherlands
EFSD
and
Juvenile Diabetes Research Foundation (JDRF)
and
Novo Nordisk A/S

European Programme in Type 1 Diabetes Research

Background

The mission of the Juvenile Diabetes Research Foundation International (JDRF) is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novo Nordisk has companies and information offices in more than 60 countries.

Plan

The partners have established the EFSD/JDRF/Novo Nordisk Programme in Type 1 Diabetes Research to foster multi-disciplinary research targeted at finding a cure for type 1 diabetes and its complications. The specific goals of the Programme are: to promote the highest quality of basic and clinical biomedical research in Europe and its associated countries applicable to type 1 diabetes, to expedite the practical application of scientific advances in our understanding of the aetiology, pathogenesis, treatment and prevention of type 1 diabetes and its complications, to encourage clinical translational research bridging the bench and the bedside, and to increase awareness of type 1 diabetes research throughout Europe.

Funding Instruments

Euro 2.25 million has been made available, from 2004 to 2006, for focused research grants of up to Euro 100,000 to be distributed each year.
Awards in 2006

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 100,000:

Luc Bouwens: Brussels University - Belgium
Per-Ola Carlsson: Uppsala University - Sweden
Paolo Madeddu: Bristol University - U.K.
Thomas Mandrup-Poulsen: Steno Diabetes Center - Gentofte, Denmark
Emmanuel Van Obberghen: Nice University Hospital - France
Ana María Wägner: Steno Diabetes Center - Gentofte, Denmark
European Studies on Glucose Monitoring

Background

For more than two decades LifeScan has been committed to improving the quality of life for people with diabetes. LifeScan helped bring blood glucose testing out of the laboratory and into the hands of patients.

Plan

The EFSD/LifeScan Awards are intended to stimulate and accelerate European research aimed at improved understanding of the optimal use of glucose monitoring tools, both in type 1 and type 2 diabetes.

Funding Instruments

A total of Euro 1 million has been made available for the purpose of offering research grants of up to Euro 100,000 each over a period of five years from 2005 to 2009. In addition, Euro 400,000 was made available to support studies on standardisation of HbA1c measurement.

Awards in 2006

Based on the recommendations of the Review Committee, the Programme Board made the following award of Euro 200,000:

Giel Nijpels: EMGO Institute - Amsterdam, The Netherlands

HbA1c Measurement

Based on the recommendations of the Review Committee, the Programme Board made an award of Euro 400,000 for joint studies on HbA1c measurement to the following:

Robert Heine: Vrije University Medical Centre - Amsterdam, The Netherlands
Charlotte Glümer: Steno Diabetes Center - Gentofte, Denmark
EFSD
and
Merck Sharp & Dohme (MSD)

European Study Programme on Beta Cell Function and Survival

Background

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Plan

These programme awards are intended to stimulate and accelerate European research into all aspects of beta cell function and survival, with particular emphasis on the following: increasing beta cell mass/function, mechanisms of glucose-stimulated insulin secretion, mechanisms of beta cell dysfunction, including beta cell gluco- and lipotoxicity, non-invasive imaging of beta cells, and beta cell intermediary metabolism.

Funding Instruments

A total of Euro 1.4 million has been made available for the two year period 2005 – 2006 in the form of research grants of up to Euro 100,000 each.

Awards in 2006

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 100,000:

- Lena Eliasson: Lund University - Sweden
- Jorge Ferrer: Fundacio Clinic - Barcelona, Spain
- Françoise Homo-Delarche: Paris 7 University - France
- Leif Jansson: Uppsala University - Sweden
- Andreas Lechner: Ludwig-Maximilians-University - Munich, Germany
- Michael Ristow: Jena University - Germany
- Stephan Schneider: Ruhr-University Bochum - Germany
- Anders Tengholm: Uppsala University - Sweden
EFSD
and
Pfizer Inc.

Resource Awards

**Background**

Pfizer is one of the world's leading healthcare companies, providing human and animal pharmaceuticals, as well as consumer products. With a portfolio that includes five of the world's 20 top-selling medicines, Pfizer is helping to improve the lives of people the world over.

**Plan**

The aim of these awards is to allow for development of resources for diabetes research, which will be available on an open-access basis or at nominal cost to all researchers in the field in Europe. Examples might be products for research (e.g. gene microarrays), biological material (e.g. cell lines), a database or co-ordination and integration of samples/data from ongoing multi-centre endeavours (e.g. genetic screening).

**Funding Instruments**

A total of **Euro 400,000** was made available for 2004 and 2005, in order to fund annual awards in each of these years in a variable sum, depending upon the needs of the proposed resource. A further Euro 200,000 has been made available for 2006, bringing the total commitment to **Euro 600,000**.

**Award in 2006**

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 200,000:

- **Daisy Flamez**: Brussels University - Belgium
- **David Dunger**: University of Cambridge - U.K.
Clinical Research Grant on the Usefulness of CSII in Microalbuminuric Type 1 Diabetic Patients

Background
The earliest clinical manifestation of diabetic nephropathy is microalbuminuria. In people with type 1 diabetes, microalbuminuria can progress to overt nephropathy and even to end-stage renal disease. Hyperglycaemia has been shown to be a very important factor associated with the degree of glomerulopathy in incipient nephropathy, and improved metabolic control has been shown to arrest, and even reverse, glomerular changes.

Plan
The research project will test the usefulness of CSII in microalbuminuric type 1 diabetic patients and, in particular, investigate if real-time glucose sensing could further benefit this patient population by reducing post-prandial hyperglycaemia.

Funding Instruments
In 2006 a fixed sum for one grant of Euro 50,000 per annum for three consecutive years was made available. Total funding for the project therefore amounts to **Euro 150,000**.

Award in 2006
Based on the recommendations of the Review Committee, the Programme Board made the following award of Euro 150,000:

Antonio Tiengo: University of Padova - Italy
EFSD
and
Amylin Pharmaceuticals Inc.

Paul Langerhans Grant on the
Integrated Physiology of the Entero-Insular Axis
and the Brain in Metabolic Homeostasis

Background

Amylin Pharmaceuticals Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialisation of innovative medicines. The company was founded in 1987 and since then has built a strong foundation on research and development. Amylin currently has two first in class diabetes drugs approved and marketed in the United States.

This grant honours the memory of Paul Langerhans, who discovered the islet cells of the pancreas.

Plan

EFSD and Amylin have established a new partnership for studies on integrated physiology of the entero-insular axis and the brain in metabolic homeostasis, to encourage new projects aimed at advancing current knowledge, and to stimulate and accelerate European research in this domain.

Funding Instruments

Grants of up to Euro 100,000 were made available in 2006.

Awards in 2006

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 100,000:

Rémy Burcelin: Hôpital Rangueil - Toulouse, France
Filip Knop: Copenhagen University - Denmark
EFSD
and
sanofi-aventis

European Programmes for the Study of:

The Endocannabinoid System from Bench to Bedside
and
Management of Diabetes and Blood Glucose Abnormalities in Patients with Cardiovascular Disease

Background

The sanofi-aventis Group is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas, and produces several medicines to treat diabetes including insulin. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis.

Plan

EFSD and sanofi-aventis have created two European programmes for studies in the following areas:

- The Endocannabinoid System from Bench to Bedside will focus on the integration of central and peripheral control of fuel and energy metabolism and its role in the pathophysiology of multiple cardiometabolic risk factors, including insulin resistance and type 2 diabetes. This programme supports both basic and clinical research.

- Management of Diabetes and Blood Glucose Abnormalities in Patients with Cardiovascular Disease supports clinical research in this field of study.

Funding Instruments

A total of Euro 2.1 million has been made available between 2006 - 2008, in order to fund annual awards in each of these years in variable sums. The awards will be administered between 1 to 3 years as deemed appropriate by the Review Committee and Programme Board.
Awards in 2006

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

The Endocannabinoid System from Bench to Bedside

This Programme funded grants totalling Euro 275,000 to the following:

Beat Lutz: Mainz University - Germany
Margot Umpleby: Surrey University - U.K.

Management of Diabetes and Blood Glucose Abnormalities in Patients with Cardiovascular Disease

This Programme funded a grant totalling Euro 200,000 to the following:

Eugenio Picano: Institute of Clinical Physiology - Pisa, Italy
EFSD

Grant Award for Collaborative Diabetes Research between China and Europe

Supported by Bristol-Myers Squibb Company (BMS)

Plan

EFSD has established a new Grant Award for Collaborative Diabetes Research between China and Europe to encourage new projects aimed at advancing current knowledge in this domain and to support diabetes research. The EFSD Grant Award is intended to stimulate and accelerate the co-operation between researchers in China and Europe for research into diabetes.

The project should be carried out in China, but performed in co-operation with a European research centre.

Funding Instruments

In 2006 Euro 200,000 was made available for research grants of up to Euro 50,000 each.

Awards in 2006

Based on the recommendations of the Review Committee, the Programme Board made the following awards, each of up to Euro 50,000:

Dai-Qing Li: Tianjin Medical University, in collaboration with Malmö University Hospital, Sweden
Guangwei Li: China-Japan Friendship Hospital, in collaboration with Aarhus University Hospital, Denmark
Zhiguang Zhou: Central South University, in collaboration with the University of London, U.K.
NEW/RENEWED PROGRAMMES IN 2007
Clinical Research Grant in Type 2 Diabetes

**Background**

Clinical research in Europe, and especially investigator-driven research, is underfunded, and an increasing number of major clinical trials are carried out in non-European countries.

Therefore, the Executive Committee of EFSD decided to stimulate clinical research in Europe by providing this new funding instrument. The aim is to increase the number of centres in Europe providing high quality clinical research, and to make an independent financial contribution to this field of research, in order to encourage investigator-driven research.

**Plan**

The EFSD Clinical Research Grant Programme will accept applications in the field of type 2 diabetes, covering all aspects of the disease, e.g. epidemiology/genetics of prediabetes, diabetes and its micro- and macrovascular complications, pathophysiology and clinical aspects including vascular physiology and obesity.

**Funding Instruments**

Grants of up to Euro 300,000 will be made available in 2007. Funds will be distributed over 3 years.

**Awards in 2007**

The deadline for applications was 1 December 2006, with an anticipated award date of February 2007.
EFSD
and
Novartis A/S

European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction

Background

Novartis is a world leader in the research and development of products to protect and improve health and well-being. Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz.

Plan

The EFSD/Novartis European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction will accept both basic and clinical projects in order to stimulate and accelerate European clinical research into all aspects of pancreatic islet dysfunction. This programme will target the clinical physiology and natural history of pancreatic islet dysfunction as it pertains to diabetes and other dysglycaemic conditions.

Funding Instruments

Up to Euro 1.2 million has been made available over 3 years, and distributed through the annual award of fixed sum grants, each of up to Euro 200,000.

Awards in 2007

The deadline for applications was 15 December 2006, with an anticipated award date of February 2007.
Young Investigator Awards

**Background**

AstraZeneca is one of the world's leading pharmaceutical companies, dedicated to the discovery, development, manufacturing and marketing of high quality, effective prescription medicines.

**Plan**

The new EFSD/AstraZeneca Young Investigator Awards have been established to promote increased European research in diabetes and train young scientists within Europe during their transition towards independence.

**Funding Instruments**

**Euro 300,000** will be made available in 2007 for the Young Investigator Awards. Each Award will comprise Euro 50,000 per annum for a total of Euro 100,000, payable over 2 years.

**Awards in 2007**

The deadline for applications will be 15 May 2007, with an award date of July 2007.
European Clinical Research Programme in Adolescents with Type 2 Diabetes

**Background**

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 60 countries.

**Plan**

The goals of the Programme are as follows: to promote the highest quality of clinical medical research in Europe and its associated countries applicable to type 2 diabetes in adolescents; to expedite the practical application of scientific advances in our understanding of the psycho-social conditions, aetiology, pathogenesis, treatment and prevention of type 2 diabetes and its complications in adolescents; to encourage clinical translational research bridging bench and bedside.

**Funding Instruments**

This new EFSD/Novo Nordisk Programme will provide Euro 900,000 for the three year period 2007 – 2009. Grants of up to Euro 100,000, will be distributed annually.

**Awards in 2007**

The deadline for applications is anticipated to be 5 July 2007, with an award date of November 2007.
EFSD and
Juvenile Diabetes Research Foundation (JDRF) and
Novo Nordisk A/S

Newly extended
European Programme in Type 1 Diabetes Research

Background

The mission of the Juvenile Diabetes Research Foundation International (JDRF) is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novo Nordisk has companies and information offices in more than 60 countries.

Plan

The goals of the Programme are to foster multi-disciplinary research targeted at finding a cure for type 1 diabetes and its complications. The specific goals of the Programme are: to promote the highest quality of basic and clinical biomedical research in Europe and its associated countries applicable to type 1 diabetes, to expedite the practical application of scientific advances in our understanding of the aetiology, pathogenesis, treatment and prevention of type 1 diabetes and its complications, to encourage clinical translational research bridging the bench and the bedside, and to increase awareness about type 1 diabetes research throughout Europe.

Funding Instruments

This new EFSD/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research will commit up to Euro 2.7 million for the 3 year period 2007 – 2009. This extends the original Programme with a new combined total of up to Euro 4.95 million. Grants of up to Euro 100,000, will be made available each year.

Awards in 2007

The deadline for applications is anticipated to be 5 July 2007, with an award date of November 2007.
FELLOWSHIPS

AWARDED IN

2006
The objective of the EFSD/Eli Lilly Research Fellowships is to encourage research in the fields of metabolism and complications of diabetes, and to promote excellence in medical education.

Two Fellowships of up to Euro 50,000 each are awarded annually from the EFSD/Eli Lilly Fund. Application may be made by any paid-up member of EASD under the age of 40 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

These Fellowships will be available for the period 2006 – 2008 inclusive as part of the EFSD/Eli Lilly European Diabetes Research Fund.

In 2006 the awardees were:

Karim Bouzakri: Karolinska Institute - Stockholm, Sweden
Sarah Longnus: Nice University Hospital - France
EFSD/AstraZeneca Research Fellowship

The objective of the EFSD/AstraZeneca Research Fellowship is to encourage diabetes research. A specific focus area is chosen each year. For 2006, this was in the field of islet biology. Applications from candidates seeking to understand better the mechanism of beta cell gluco/lipotoxicity or the link between obesity, type 2 diabetes and islet function were particularly encouraged.

One Fellowship is awarded annually in the sum of Euro 50,000. Applications will be considered from any paid-up member of EASD under the age of 40 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

In 2006 the awardee was:

Hannah Welters: Peninsula Medical School - Plymouth, U.K:

EFSD/AstraZeneca Clinical Travel Fellowships

The EFSD/AstraZeneca Clinical Travel Fellowships enable young clinicians to travel and stay at other institutions in order to learn new clinical skills or techniques in clinical diabetes research. The duration of the stay should be suited to the training purpose and must not exceed two months.

Each Fellowship is in the amount of up to Euro 5,000 dependent on the length of stay, local costs and costs of travel. In addition, Euro 1,000 will be paid to the host institution to defray costs of training.

In 2006 the following Fellowships were awarded:

Agbor Ndip Ebok Ako: travelled to the University of Manchester - U.K.  
Akinola Olusola Dada: travelled to Heinrich Heine University - Düsseldorf, Germany  
Henry Onyegbutulem: travelled to Carl Gustav Carus University Hospital - Dresden, Germany  
Tunji Olugbenga Oyewole: travelled to the University of Freiburg - Germany  
Nina Petrova: travelled to Botnar Research Centre - Oxford, U.K.
The objective of the EFSD Research Fellowships is to encourage research in the field of diabetes and metabolism and to promote excellence in medical education. Applicants should have demonstrated their ability in the field of diabetes research.

Two Travel Fellowships, each of Euro 25,000, will be made available to successful applicants from China. This amount is meant to support travel and living expenses for a period of time ranging from 3 to 6 months, to be spent in a European institution.

In 2006 the following Fellowships were awarded:

Yuying Ma: travelled to the University of Surrey - U.K.
Lei Zhou: travelled to the German Diabetes Center - Düsseldorf, Germany
EFSD/Albert Renold Fellowships

Professor Albert Ernst Renold (1923-1988) was the founding Secretary of the European Association for the Study of Diabetes (EASD) from 1965-1970 and later served as President of EASD from 1974-1977. He was also President of the International Diabetes Federation from 1979-1982. He played a major role in advancing diabetes research both in Europe and throughout the world. To commemorate the considerable debt owed to Albert Renold for his inspirational leadership, and to help the most promising young investigators acquire new skills in diabetes research by visiting another laboratory, EFSD has established the Albert Renold Fellowship programme.

EFSD Albert Renold Fellowships, each amounting to up to Euro 6,000, will enable young scientists to travel to and stay at other institutions in order to learn new techniques in basic or clinical diabetes research. The duration of the stay should not exceed three months. Applications will be considered from any paid-up member of EASD under the age of 35 years (PhD) or 40 years (MD/PhD with clinical training) on 1 January in the year of the award. EFSD/Albert Renold Fellowships are available throughout the year, and a decision is usually made within a few weeks of applying.

The EFSD Albert Renold Fellowship Programme is supported by an unrestricted educational grant from Merck Sharp & Dohme (MSD).

In 2006 the following Fellowships were awarded:

Adam Baker: travelled to Sahlgrenska Academy - Göteborg, Sweden
Silvia Casas Fontdevila: travelled to Cambridge Institute for Medical Research - U.K.
Ioana Chisalita: travelled to the EASD Scientists Training Course - Perugia, Italy
Ivana Cvetkovic: travelled to Uppsala University - Sweden
José Luis González-Sánchez: travelled to Karolinska Institute - Stockholm, Sweden
Tereza Grimmichova: travelled to the University of Virginia - U.S.A.
Andrea Grosso: travelled to the Royal Victorian Eye & Ear Hospital - Melbourne, Australia
Susanne Günnel: travelled to the University of Cincinnati - U.S.A.
Yaomin Hu: travelled to the University of Oxford - U.K.
Ilze Konrāde: travelled to the University of Heidelberg - Germany
Anja Mayr: travelled to Guy’s, King’s & St Thomas’ School of Medicine - London, U.K.
Giuseppe Murdolo: travelled to Lundberg Laboratory for Diabetes Research - Göteborg, Sweden
Konstantin Nizheradze: travelled to the University of Turin - Italy
Anthonia Ogbera: travelled to the University of Newcastle upon Tyne - U.K.
Miguel Pinto: travelled to the University of Turku - Finland
Emina Sudar: travelled to The National Institute of Occupational Health - Oslo, Norway
Laura Welschen: travelled to the University of Cambridge - U.K.
EFSD Review Committee Members

EFSD is most grateful to the following colleagues who served in on the various review committees of the 2006 partnership programmes:

Angelo Avogaro (I) John Pickup (UK)
Angelika Bierhaus (D) Thomas Pieber (A)
Klaus Badenhoop (D) Flemming Pociot (DK)
Polly Bingley (UK) Massimo Porta (I)
Bernard Otto Böhm (D) Erik Renström (S)
Christian Boitard (F) Bart Roep (NL)
Geremia Bolli (I) Johannes A. Romijn (NL)
Riccardo Bonadonna (I) Peter Rossing (DK)
Fatima Bosch (E) Guy Rutter (UK)
Rémy Burcelin (F) Carani Sanjeevi (S)
Marc Donath (CH) André Scheen (B)
Eva Feldman (USA) Jean-Louis Selam (USA)
Jorge Ferrer (E) Giorgio Sesti (I)
Allan Flyvbjerg (DK) Olli Simell (FIN)
Peter Grant (USA) Ulf Smith (S)
Valdemar Grill (N) Michele Solimena (D)
Hans-Peter Hammes (D) Giatgen Spinas (CH)
Kristian Hanssen (N) Eberhard Standl (D)
Stephen Herzig (D) Philippe-Gabriel Steg (F)
Peter Jones (UK) Cœn Stehouwer (NL)
Pierre Maechler (CH) Michael Stumvoll (D)
Michel Marre (F) Markus Tiedge (D)
Andrea Natali (I) Paul Valensi (F)
Michael Nauck (D) Luc Van Gaal (B)
Uberto Pagotto (I) Antonio Vidal-Puig (UK)
Kenneth Paterson (UK) Mark Walker (UK)
Andreas Pfeiffer (D) Hannele Yki-Järvinen (FIN)
EFSD EXECUTIVE COMMITTEE and ADMINISTRATION

Executive Committee:
President: Prof E Ferrannini - Pisa
Vice President: Prof U Smith - Göteborg
Vice President: Prof C Boitard - Paris
Honorary Secretary: Prof D L Eizirik – Brussels
Adjunct Honorary Secretary: Prof M Stumvoll - Leipzig
Honorary Treasurer: Prof G Spinas - Zurich
Editor in Chief - Diabetologia: Prof E Gale – Bristol
Chairman PGESC: Prof J Nolan - Dublin

Chairman, Advisory Board: Prof P A Halban – Geneva
Senior Advisor: Prof J Nerup – Gentofte
Members:
Dr J Ferrer - Barcelona
Prof M Walker – London

Executive Director: Dr V Jörgens - Düsseldorf
Administrators: Sara Burgess - Düsseldorf
Kathrin Sommer – Düsseldorf

The European Foundation for the Study of Diabetes (EFSD)
Rheindorfer Weg 3
40591 Düsseldorf, Germany

Tel: +49 211 75 84 69-0 Fax: +49 211 75 84 69-29

www.EuropeanDiabetesFoundation.org
Email: Foundation@easd.org

Bank details
Europäische Stiftung für Diabetesforschung – EFSD
Dresdner Bank
Königsallee 37
40212 Düsseldorf, Germany

Account / Konto: 600 2146 00 Code / BLZ: 300 800 00

SWIFT / BIC: DRES DE FF 300

IBAN: DE31 3008 0000 0600 2146 00

EFSD is registered as a non-profit Foundation in Düsseldorf, Germany under registration number: 15.2.1-St.767
and at the Inland Revenue in Düsseldorf, Germany under tax number: 106/5744/1547

The EFSD Accounts for the fiscal year 2005 were submitted to the German Inland Revenue. Following detailed
evaluation, a Certificate was issued endorsing the status of EFSD as a charity. This Certificate is held on file at the
EFSD office and a copy can be made available upon request.